News

News | June 3, 2019

Carisma Therapeutics Names Dr. Robert Petit As Chief Scientific Officer

Read More

News | May 27, 2019

Carisma Therapeutics Featured in Nature Biotechnology’s Top Academic Spin-outs 2018

Read More

News | April 9, 2019

Pliant Therapeutics Reports Positive Results Of Phase 1 Clinical Study

Read More

News | March 1, 2019

Genome editing company Precision proposes $100M IPO

Read More

News | January 3, 2019

Pliant Therapeutics Initiates Phase 1 Clinical Study of PLN-74809

Read More

News | December 18, 2018

Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita

Read More

News | November 27, 2018

Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy

Read More

News | November 20, 2018

Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Primary Sclerosing Cholangitis

Read More

News | November 5, 2018

Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering

Read More

News | June 27, 2018

Carisma Nabs $53 Million Series A for Cellular Cancer Therapy

Read More